miRagen has three product candidates in clinical development:
- Cobomarsen (MRG-106), an inhibitor (LNA antimiR®) of microRNA-155, is being developed for the treatment of blood cancers;
- MRG-201, a synthetic microRNA mimic (promiR) of microRNA-29b is being developed for the treatment or prevention of pathologic fibrosis; and,
- MRG-110 (S95010), a synthetic microRNA inhibitor (LNA antimiR®) of microRNA-92, is being developed in collaboration with Servier for treatment of ischemic conditions including heart failure, as well as incisional complications and wound healing.
For detailed trial information, please click here.